The Sotac Pharmaceuticals IPO has begun on 29-Mar 2023. It will close on 03 APR 2023. The Total IPO Size is 33.30 Crore. The company set its IPO price is 111 Rs Per Share. Basically, There are three basic categories in Sotac Pharmaceuticals IPO Subscription 1) Non-Institutional Investors 2) Retail Individual Investors (RIIs) 3) QIB
Sotac Pharmaceuticals are in business of manufacturing of pharmaceutical products for different marketers on loan license or contract manufacturing basis. They have 162 corporate clients on loan licence and/or contract manufacturing basis.
The Company has marked its presence in both domestic as well as global markets. Our products are supplied in 14 major states in India.The offshore business revenue is primarily derived from USA. The pharmaceutical manufacturing facilities are situated at Sanand GIDC–II in Ahmedabad district of Gujarat.
The group’s therapeutic portfolio includes Anti-Diabetic, Anti-Psychotic, Vitamins, Minerals, Iron, Anti-Cold, AntiAllergic, Derma Products, Antacid, Anti-Ulcerants, PPI, Anti-Emetics, Cardiac, Anti-Hypertensives, Analgesic, AntiPyretic, Anti-Inflammatory, Anti-Bacterial, Anti-Viral, General Antibiotics IP-Lactams & Non-IP-Lactams, Anti-Fungal, Cephalosporin.
The group’s past and present clientele includes renowned pharma marketers and manufactures namely Cadila Pharma, J. B. Chemical, Lincoln Pharma, Intas Pharma, Viatris (Mylan), Makers (Ipca), Corona Remedies, Eris Lifesciences, Stride Pharma, Stalion Pharma, Acme Pharma, Olecare Pharma, Treatwell Pharma, Ronak Healthcare, Curever Pharma, Kentoss Pharma, Sunrest Pharma, Ishan Healthcare etc.
|Latest News Update: Sotac Pharmaceuticals IPO Subscription Status Live|
|Day 1 (times)||Day 2 (times)||Day 3 (times)|